Effects of 1.ALPHA.-hydroxyvitamin D3 on experimental uremic renal osteodystrophy in rats induced by Na-sulfacetylthiazole.

Publisher Website
Google Scholar
Abstract
Sodium sulfacetylthiazole (SAT), 0.1 g/kg body wt as 5% aqueous solution, was injected i.p. to Wistar male rats weighing 200 to 300 g, twice a week for 1, 2 and 4 mo., while 1.alpha.-hydroxyvitamin D3 (1.alpha.-OH-D3) was simultaneously administered orally to a half of the SAT-4 mo.-treated rats at a daily dose of 0.25 .mu.g/kg body wt for the last 19 days of the feeding period. Both blood urea nitrogen (BUN) and serum inorganic P concentrations were markedly increased and the histological examination of the kidneys of SAT-treated rats revealed interstitial nephritis. Serum Ca level was significantly decreased in the rats treated with SAT for 2 or 4 mo. Serum parathyroid hormone (PTH) level as well as the wet weight of parathyroid glands was increased in SAT-treated rats, while simultaneous administration of 1.alpha.-OH-D3 inhibited such increases. Serum 25-hydroxyvitamin D3 (25-OH-D3) was decreased in the rats treated with SAT for 2 mo. The X-ray density and Ca content of the femurs of SAT-treated rats were decreased, while simultaneous administration of 1.alpha.-OH-D3 inhibited such decreases. Tetrachrome stain of the femurs of SAT-4 mo.-treated rats revealed a marked increase of osteoid contents in the bone cortex, while 1.alpha.-OH-D3 inhibited such an increase in osteoid formation. 1.alpha.-OH-D3 would be effective for the treatment of uremic renal osteodystrophy, although its detailed mechanism remains to be further clarified.